| Page 7 | Aplastic Anemia and MDS International Foundation (AAMDSIF)

How I use maintenance therapy in acute myeloid leukemia

Abstract
Outcomes for

TP53-Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis

ABSTRACT
Patients with TP53 mutations in

Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia

Dear Editor,

Real-World Outcomes of Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study

To the Editor,
Core-binding factor

Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms

Abstract

Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study

Author(s):

Garelius HKG, Bagguley T, Taylor A, Fenaux P, Bowen D, Symeonidis A, Mittelmann M, Stauder R, Čermák J, Sanz G, Langemeijer S, Malcovati L, Germing U, Sanhes L, d'Aveni M, Culligan D, Kotsianidis I, Koinig KA, van Marrewijk C, Crouch S, deWitte T, Smith A

Primary Author:

Garelius HKG

Journal Title:

Lancet Haematology

Original Publication Date:

Feb 2025

Background: In our previous study on erythropoiesis-stimulating agent (ESA) treatment in lower risk

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes

Author(s):

King Z, Desai SR, Frank DA, Shastri A.

Primary Author:

King Z

Journal Title:

Neoplasia

Original Publication Date:

Mar 2025

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Genome sequencing in the management of myelodysplastic syndromes and related disorders

Author(s):

Cazzola M, Malcovati L

Primary Author:

Cazzola M

Journal Title:

Haematologica

Original Publication Date:

Feb 2025

Myeloid neoplasms originate from the clonal proliferation of hematopoietic

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Diagnosis of myelodysplastic syndromes: the classic and the novel

Author(s):

Oster HS, Van de Loosdrecht AA, Mittelman M

Primary Author:

Oster HS

Journal Title:

Haematologica

Original Publication Date:

Feb 2025

The

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)

Treatment of high-risk myelodysplastic syndromes

Author(s):

Kröger N

Primary Author:

Kröger N

Journal Title:

Haematologica

Original Publication Date:

Feb 2025

Myelodysplastic syndrome (MDS) is considered to be a heterogeneous myeloid malignancy with a common origin in the hematopoietic stem cell compartment and is generally divided into lower- and higher-risk forms. While the treatment goals for lower-risk MDS are to decrease transfusion requirements and transformation into acute leukemia, the major aims for higher-risk MDS are to prolong survival and ultimately cure the patient.

Bone Marrow Disease(s):

Myelodysplastic Syndromes (MDS)